Targos Molecular Pathology

Targos Molecular Pathology provides  premier biomarker services in clinical trials under GCP conditions for top tier international  pharmaceutical and diagnostic companies.

In the companies' state-of the art laboratory facilities, all techniques to analyze biomarkers - such as IHC, ISH, mutation analysis, parallel sequencing, ELISA and/or digital pathology are established. New assays are also added and validated constantly upon demand.

 

Targos Molecular Pathology supports global clinical trials with pathology services through board certified pathologists, project management through PhD trained managers, logistics (e.g., sample kits, sample pick-up, re-shipment, storage, archiving), data/quality management, assay development, consulting and  training according to full GCP standards.

Targos is regularly audited by our pharma customers and the FDA.

The CAP Certification Mark is a service mark owned by CAP and is used pursuant to a license from CAP.

CLIA Certificate of Compliance or Accreditation (click here to view)